Mubadala SEC filing dated Nov. 16 does not establish that it exited Gilead stake
Key Facts
A search result in the U.S. Securities and Exchange Commission’s filings database shows a 13F-HR filing under Mubadala Investment Company, bearing a signature date of Nov. 16, 2026. But the original document could not be opened to verify the holding details, so the available record does not establish that the fund liquidated its entire stake in Gilead Sciences. The information that could be verified also does not detail the position the fund held or any change to it. 13F reports are filed within 45 days of the end of each quarter, making them a periodic snapshot that lags the date of the positions. The commission’s filing calendar set Nov. 16 as the deadline for third-quarter 2026 reports. The filing date alone therefore does not establish when any investment move occurred or explain its rationale.
Against that disclosure backdrop, Gilead said product sales rose 13% to $8.3 billion in the third quarter of 2026 compared with the same period a year earlier. The company attributed the increase mainly to HIV products and the drugs Trodelvy and Livdelzi, partly offset by lower sales of Veklury and cell therapy products. Product sales excluding Veklury grew 16% to $8.2 billion. Chief Executive Daniel O’Day said year-over-year growth in the core business was the strongest in more than a decade, adding that the company had again raised its core business revenue outlook. The results provide context on the company’s operating performance alongside the news of the institutional investor’s filing, without revealing any link between them.
HIV products were among the main sales drivers, with revenue rising 18% to $6.2 billion in the third quarter. Gilead attributed the increase mainly to a higher average realized price, demand for HIV prevention and favorable inventory dynamics. Biktarvy sales rose 10% to $4.1 billion, driven mainly by demand, realized price and inventory. By contrast, Veklury sales fell 69% to $86 million, which the company attributed mainly to fewer COVID-19-related hospitalizations. The products’ varying performance reflects their differing contributions to the quarter’s results, while the available Mubadala filing does not provide enough detail to link those results to a decision on the stock.
Gilead raised its 2026 product sales outlook to a range of $31.0 billion to $31.3 billion, compared with a previous range of $30.1 billion to $30.4 billion in its Aug. 4 update. On earnings, diluted earnings per share under generally accepted accounting principles were $1.94 in the third quarter, versus $2.43 in the same period of 2025. The company partly attributed the decline to securities losses and higher expenses and taxes. It also said cash, cash equivalents and marketable securities totaled $6.4 billion on Sept. 30, compared with $10.6 billion on Dec. 31, 2025. The company attributed the decline mainly to cash outflows for acquisitions, debt repayments, distributions and share repurchases. These indicators show different aspects of the company’s results, but do not establish a reason for any potential change in Mubadala’s holding.
Gilead shares closed at $168.08 on Nov. 13, 2026, according to EL7 data. That price is from a session before the signature date of the filing shown in the commission’s record and does not, by itself, establish the market’s reaction to the disclosure. The company declared a quarterly dividend of $0.82 a share for the fourth quarter of 2026, payable on Dec. 30 to shareholders of record on Dec. 15. It said future dividends remain subject to board approval. The company also said the maximum fair price for Biktarvy under the Medicare program will take effect and affect the drug’s revenue starting Jan. 1, 2028. The size of Mubadala’s Gilead holding, and whether it changed, remain unverifiable from the document that could be accessed.